Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 6:13:1080108.
doi: 10.3389/fendo.2022.1080108. eCollection 2022.

Liquid levothyroxine formulations in patients taking drugs interfering with L-T4 absorption

Elisa Gatta  1 , Francesca Bambini  1 , Caterina Buoso  1 , Maria Gava  1 , Virginia Maltese  1 , Valentina Anelli  1 , Andrea Delbarba  1 , Ilenia Pirola  1 , Carlo Cappelli  1
Affiliations
Review

Liquid levothyroxine formulations in patients taking drugs interfering with L-T4 absorption

Elisa Gatta et al. Front Endocrinol (Lausanne). .

Abstract

Purpose: To describe the current knowledge on thyroid hormonal profile in patients on liquid L-T4 therapy and drugs known to interfere with L-T4 absorption.

Methods: A PubMed/MEDLINE, Web of Science, and Scopus research was performed. Case reports, case series, original studies and reviews written in English and published online up to 31 August 2022 were selected and reviewed. The final reference list was defined based on the relevance of each paper to the scope of this review.

Results: The available data showed that novel levothyroxine formulations circumvent gastric pH impairment due to multiple interfering drugs such as proton pump inhibitors, calcium or iron supplements, sevelamer, aluminum/magnesium hydroxide and sodium alginate.

Conclusion: New formulations can be taken simultaneously with drugs interfering with L-T4 absorption, in particular liquid formulations. Softgel capsules need more studies to support these data.

Keywords: interfering drugs; levothyroxine; levothyroxine malabsorption; liquid levothyroxine; softgel capsules.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
See this image and copyright information in PMC

References

    1. McAninch EA, Bianco AC. The history and future of treatment of hypothyroidism. Ann Intern Med (2016) 164(1):50–6. doi: 10.7326/M15-1799 - DOI - PMC - PubMed
    1. Colucci P, D'Angelo P, Mautone G, Scarsi C, Ducharme MP. Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther Drug Monit (2011) 33(3):355–61. doi: 10.1097/FTD.0b013e318217b69f - DOI - PubMed
    1. Benvenga S, Bartolone L, Squadrito S, Lo Giudice F, Trimarchi F. Delayed intestinal absorption of levothyroxine. Thyroid (1995) 5(4):249–53. doi: 10.1089/thy.1995.5.249 - DOI - PubMed
    1. Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab (2009) 23(6):781–92. doi: 10.1016/j.beem.2009.06.006 - DOI - PubMed
    1. Bach-Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab (2009) 94(10):3905–12. doi: 10.1210/jc.2009-0860 - DOI - PMC - PubMed

LinkOut - more resources